What it is
KPV is shorthand for Lysine-Proline-Valine, a three amino acid fragment that sits at the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically residues 11 to 13. Alpha-MSH itself is best known for controlling skin pigmentation, which is the mechanism behind Melanotan 1 and Melanotan 2. KPV is the opposite kind of fragment: researchers cut it down to the smallest piece that still calms inflammation in cell and animal experiments, without the pigmentation-driving part of the molecule attached.
It shows up almost exclusively in gut inflammation research, where it is studied as a possible lead compound rather than a finished drug.
How it works
Alpha-MSH normally acts through melanocortin receptors, of which MC1R (in skin) and MC1R on immune cells are the best studied. What made KPV notable is that its anti-inflammatory effect in early cell studies did not depend on classical melanocortin receptor signalling the way the rest of the alpha-MSH molecule does. That distinction is why researchers kept studying the fragment on its own instead of just using full alpha-MSH.
Dalmasso and colleagues (2008) traced a specific route into the cell: intestinal epithelial cells take up KPV through PepT1, a transporter normally used to absorb short peptides from digested food. Once inside, KPV interfered with NF-kB, a signalling hub that turns on many of the genes driving intestinal inflammation. Reducing NF-kB activity reduced downstream inflammatory cytokine production in their cell and mouse experiments.
What the research found
There is no published human data on KPV. Everything below is cell culture or mouse research.
- Kannengiesser and colleagues (2008) tested the tripeptide in mouse models of inflammatory bowel disease and reported anti-inflammatory activity, positioning KPV as a smaller, more targeted alternative to using full-length alpha-MSH.
- Dalmasso and colleagues (2008) showed PepT1-mediated uptake of KPV into intestinal epithelial cells and demonstrated reduced intestinal inflammation in their mouse colitis model, tying the effect to NF-kB suppression.
- Xiao and colleagues (2017) tackled a practical problem: KPV is a small, unstable peptide that does not survive the gut well if swallowed whole. They packaged it into hyaluronic acid-functionalized nanoparticles designed to release the peptide inside inflamed colon tissue, and reported that this oral delivery system reduced ulcerative colitis activity in their mouse model.
- Sun and colleagues (2021) took a different engineering approach, stabilising KPV in a self-cross-linked hydrogel and testing it in rats with TNBS-induced ulcerative colitis.
Read together, the pattern is consistent: KPV shows anti-inflammatory activity in cultured intestinal cells and in chemically induced mouse and rat colitis, and a growing share of the recent literature is about drug-delivery engineering to make the peptide usable orally, rather than about new biological findings. None of this has moved into a human trial.
Side effects reported in studies
No human safety data exists because no human study has been published. The animal literature does not describe adverse effects from KPV itself in the papers cited above, but animal tolerability data does not establish human safety, dosing or interactions.
KPV vs other alpha-MSH-derived peptides
| Compound | Relation to alpha-MSH | Receptor mechanism | Research focus | Human data |
|---|---|---|---|---|
| KPV | C-terminal tripeptide fragment | Anti-inflammatory effect not tied to classical melanocortin receptor signalling in the cited studies | Gut inflammation (cell, mouse, rat) | None published |
| Melanotan 1 | Full-length alpha-MSH analogue | MC1R agonist | Skin pigmentation | Human trials existed for the approved drug afamelanotide, a related analogue |
| Melanotan 2 | Modified, non-selective alpha-MSH analogue | MC1R and MC4R agonist | Pigmentation, sold for tanning and libido use | Small trials; not an approved drug |
Status in the Philippines
No KPV product is registered with FDA Philippines, and no regulator anywhere has approved it as a medicine. It is not a controlled substance under RA 9165. Locally it is sold by research-chemical suppliers, sometimes on its own and sometimes combined with other peptides in a single blended vial.
Storage
Lyophilised KPV should be kept refrigerated and protected from light before reconstitution. Once mixed with bacteriostatic water, standard peptide handling applies: store at 2 to 8°C, keep away from heat and direct sun, and discard if the vial has been left warm for an extended period, which matters during Manila brownouts. See the beginner guide for handling basics.
